NeuroOne Medical Technologies Corporation reported accelerating commercial momentum with record procedure volume for its brain ablation system and early success in treating trigeminal neuralgia, while advancing three new programs targeting markets exceeding $1 billion each. The company's OneRF® ablation system, commercialized through an exclusive distribution partnership with Zimmer Biomet, delivered its strongest quarter since launch in Q1 fiscal 2026, with nearly 50% of all ablations performed since 2024 completed in that single quarter.
Following FDA 510(k) clearance last August for its trigeminal nerve ablation system, NeuroOne has completed nine cases across three centers, with all patients reportedly pain-free. Trigeminal neuralgia affects approximately 150,000 new patients annually in the United States and is considered one of the most debilitating pain conditions. The company's limited market release is expected to be completed by the end of the second quarter of fiscal 2026, with active discussions underway regarding both direct commercialization and strategic licensing partnerships.
The company is strategically focused on three critical areas: brain, pain, and advanced drug delivery. Beyond currently approved commercial applications representing over $200 million in U.S. market opportunity, NeuroOne is pursuing three additional billion-dollar markets. Drug delivery, basivertebral nerve ablation (BVNA), and spinal cord stimulation each represent addressable markets that could exceed $1 billion annually in the U.S. The strategic interest in these larger opportunities is evidenced by transactions such as Boston Scientific's acquisition of Relievant Medsystems, developer of the Intracept® basivertebral nerve ablation system, for approximately $850 million upfront plus additional contingent payments in late 2023.
NeuroOne's drug delivery system is now six months ahead of its original development schedule, targeting commercial readiness for use in investigational clinical studies or animal studies by the end of Q3 fiscal 2026. The company is focused initially on glioblastoma, an aggressive form of brain cancer with median survival measured in months, as well as gene and cell-based therapies. Multiple advisory board meetings with leading pain specialists have confirmed the clinical rationale for the company's Basivertebral Nerve Ablation system for chronic low back pain, with advanced discussions underway with potential strategic partners.
The company has initiated a six-month animal study for its spinal cord stimulation percutaneous paddle lead in preparation for a first-in-man study, with potential strategic partners engaged in diligence discussions. The system utilizes a percutaneously-placed thin-film paddle electrode to deliver precise electrical stimulation to the spinal cord, blocking pain signals from reaching the brain. This capability opens the use of paddle electrodes to both pain management doctors and neurosurgeons, whereas currently surgeons predominantly place paddle electrodes through invasive procedures.
Financially, NeuroOne reported strong positioning with growing revenues and ample working capital. As of December 31, 2025, the company carries zero debt with $3.6 million in cash and cash equivalents, $2.7 million in accounts receivable, and $6.8 million in working capital. Product gross margin was 54.2% in Q1, with gross profit growing sequentially. The company is guiding to at least $10.5 million in product revenue for fiscal year 2026, a minimum 17% increase over fiscal year 2025, though this guidance does not include any contribution from the recent trigeminal nerve ablation clearance.
The company's growing intellectual property portfolio includes 13 U.S. patents issued or pending plus four internationally. NeuroOne will hold its Annual Meeting of Stockholders on April 3, 2026, where stockholders will vote on an amendment to effect a reverse stock split at a ratio in the range of 1-for-2 to 1-for-15 to maintain compliance with Nasdaq's continued listing requirements. The company emphasized that this is a structural compliance mechanism that leaves total market capitalization and each shareholder's proportional ownership unchanged.
